In further pre-clinical studies, co-treatment of cells with paclitaxel and a JAK2 inhibitor, NVP-BSK805, could significantly reduce STAT3 phosphorylation, and in vivo tumor growth, when compared with paclitaxel alone (67). Here, STAT3 is linked to neoplasm.